Volume 27, Issue 1 (Spring 2021)                   IJPCP 2021, 27(1): 48-63 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Saberi Zafarghandi M B, Eshrati S, Arezoomandan R, Farnia M, Mohammadi H, Vahed N, et al . Review, Documentation, Assessment of Treatment, and Harm Reduction Programs of Substance Use Disorder in Iranian Prisons. IJPCP 2021; 27 (1) :48-63
URL: http://ijpcp.iums.ac.ir/article-1-3167-en.html
1- Department of Addiction, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran. , saberi.mb@iums.ac.ir
2- Department of Addiction, School of Behavioral Sciences and Mental Health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran.
3- Education and Research Office of Iranian Prisons Organization, Tehran, Iran.
4- Trauma and Injury Research Center, Iran University of Medical Sciences, Tehran, Iran.
Abstract:   (6794 Views)
Objectives: This study aims to assess the implementation of drug-related harm reduction programs in Iranian prisons and suggest solutions for their improvement.
Methods: This study was conducted in three steps. First, library method was used for collecting data from the central library of Iran’s Prisons, Security and Corrective Measures Organization. In the second step, performance indicators were extracted based on the results of first step and two researcher-made checklists were designed. Finally, a field visit and a semi-structured interview with the authorities involved in the treatment and harm reduction services were carried out.
Results: In most of prisons, drug-related harm reduction programs were underway. Despite a lack of human resources and budget at the beginning, the quality of measures was gradually increased and the attitude of authorities was improved. Methadone Maintenance Treatment and Triangular Clinics were the most common harm reduction programs, in addition to HIV and tuberculosis screening programs in collaboration with medical sciences universities. The program continued despite the change of officials.
Conclusion: Harm reduction programs are able to reduce infection diseases, self-harm and violent behaviors in prisons of Iran. Cultural programs along with other harm reduction programs, briefings and seeking support from the authorities can greatly help with continuation of the programs in prisons. By eliminating the shortage of manpower and redefining the security areas for ordinary prisoners, it will be possible to make better use of the facilities of universities and research centers.
Full-Text [PDF 6105 kb]   (1399 Downloads) |   |   Full-Text (HTML)  (2187 Views)  
Type of Study: Original Research | Subject: Psychiatry and Psychology
Received: 2020/01/31 | Accepted: 2020/09/27 | Published: 2021/04/20

1. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug and alcohol dependence. 2009; 105(1-2):83-8. 10.1016/j.drugalcdep.2009.06.015 [DOI:10.1016/j.drugalcdep.2009.06.015] [PMID] [PMCID]
2. Blaauw E, Roesch R, Kerkhof A. Mental disorders in European prison systems: Arrangements for mentally disordered prisoners in the prison systems of 13 European countries. International Journal of Law and Psychiatry. 2000; 23(5-6):649-63. 10.1016/s0160-2527(00)00050-9 [DOI:10.1016/S0160-2527(00)00050-9]
3. Zamani S, Farnia M, Tavakoli S, Gholizadeh M, Nazari M, Seddighi A-A, et al. A qualitative inquiry into methadone maintenance treatment for opioid-dependent prisoners in Tehran, Iran. International Journal of Drug Policy. 2010; 21(3):167-72. 10.1016/j.drugpo.2009.03.001 [DOI:10.1016/j.drugpo.2009.03.001] [PMID]
4. Huby RH, Meg. Life in prison: perspectives of drug injectors. Deviant Behavior. 2000;21(5):451-79. [DOI:10.1080/01639620050085843]
5. Eshrati B, Asl RT, Dell CA, Afshar P, Millson PM, Kamali M, et al. Preventing HIV transmission among Iranian prisoners: initial support for providing education on the benefits of harm reduction practices. Harm Reduction Journal. 2008; 5(1):21. 10.1186/1477-7517-5-21 [DOI:10.1186/1477-7517-5-21] [PMID] [PMCID]
6. Zamani S, Kihara M, Gouya MM, Vazirian M, Ono-Kihara M, Razzaghi EM, et al. Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. Aids. 2005; 19(7):709-16. 10.1097/01.aids.0000166094.24069.72 [DOI:10.1097/01.aids.0000166094.24069.72] [PMID]
7. Organization WH. Multi-city study on drug injecting and risk of HIV infection: a report prepared on behalf of the WHO International Collaborative Group. Geneva: World Health Organization, 1994.
8. Beyrer C, Jittiwutikarn J, Teokul W, Razak MH, Suriyanon V, Srirak N, et al. Drug use, increasing incarceration rates, and prison-associated HIV risks in Thailand. AIDS and Behavior. 2003; 7(2):153-61. 10.1023/a:1023946324822
9. Dolan K, Rutter S, Wodak AD. Prison‐based syringe exchange programmes: a review of international research and development. Addiction. 2003; 98(2):153-8. 10.1046/j.13600443.2003.00309.x [DOI:10.1046/j.1360-0443.2003.00309.x] [PMID]
10. Horton A. Heroin users: The need for improved treatment for incarcerated women. Social Work in Public Health. 2011;26(2):176-88. 10.1080/19371910903182773 [DOI:10.1080/19371910903182773] [PMID]
11. Jacob J, Stöver H. The transfer of harm-reduction strategies into prisons: needle exchange programmes in two German prisons. International Journal of Drug Policy. 2000; 11(5):325-35. 10.1016/s0955-3959(00)00050-5 [DOI:10.1016/S0955-3959(00)00050-5]
12. Koulierakis G, Gnardellis C, Agrafiotis D, Power KG. HIV risk behaviour correlates among injecting drug users in Greek prisons. Addiction. 2000;95(8):1207-16. 10.1046/j.1360-0443.2000.95812077.x [DOI:10.1046/j.1360-0443.2000.95812077.x] [PMID]
13. Onorato IM, McCray E, Branch FS. Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States. Journal of Infectious Diseases. 1992;165(1):87-92. [DOI:10.1093/infdis/165.1.87] [PMID]
14. Roshanfekr P, Farnia M, Dejman M. The effectiveness of harm reduction programs in seven prisons of Iran. Iranian journal of public health. 2013;42(12):1430. PMID: 26060645
15. Pourahmad M, Javady A, Karimi I, Ataei B, Kassaeian N. Seroprevalence of and risk factors associated with hepatitis B, hepatitis C, and human immunodeficiency virus among prisoners in Iran. Infectious Diseases in Clinical Practice. 2007; 15(6):368-72. 10.1097/IPC.0b013e318142ce16 [DOI:10.1097/IPC.0b013e318142ce16]
16. Zafarghandi MBS, Jadidi M, Khalili N. Iran's activities on prevention, treatment and harm reduction of drug abuse. International journal of high risk behaviors & addiction. 2015;4(4). 10.5812/ijhrba.22863 [DOI:10.5812/ijhrba.22863] [PMID] [PMCID]
17. United Nations Office on Drugs and Crime. Evaluation of substance use treatment programs (2015).https://www.unodc.org/documents/islamicrepublicofiran/publications/1jan2015/Evaluation_of_Substance_Use_Treatment_Programmes-EN.pdf
18. World Health Organization. Work book 4: process evaluation (2000). https://apps.who.int/iris/bitstream/handle/10665/66584/WHO_MSD_MSB_00.2e.pdf;jsessionid=097876A1DA8895D0405B0A22E4D9F5C4?sequence=5
19. Bayan Zadeh A, Bolhari J, Atef Vahid MK, Nouri Ghasem Abadi R, Fatali Lavasani F, & Karimi Kismi E. The role of medication and psychological interventions in harm reduction of substance use in addicted prisoners. Iranian Journal of Psychiatry and Clinical Psychology. 2007; 14(55): 47-38.
20. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. International Journal of Drug Policy. 2010;21(5):422-4. 10.1016/j.drugpo.2010.03.008 [DOI:10.1016/j.drugpo.2010.03.008] [PMID]
21. Werb D, Wood E, Small W, Strathdee S, Li K, Montaner J, et al. Effects of police confiscation of illicit drugs and syringes among injection drug users in Vancouver. International Journal of Drug Policy. 2008; 19(4):332-8. 10.1016/j.drugpo.2007.08.004 [DOI:10.1016/j.drugpo.2007.08.004] [PMID] [PMCID]
22. Shahbazi M, Farnia M, Rahmani K, Moradi G. Trend of HIV/AIDS prevalence and related interventions administered in prisons of Iran-13 years' experience. Iranian journal of public health. 2014;43(4):471. PMID: 26005657
23. Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N. The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care‐led methadone maintenance service. Addiction. 2010;105(4):732-9. 10.1111/j.1360-0443.2009.02856.x [DOI:10.1111/j.1360-0443.2009.02856.x] [PMID]
24. Moradi AR, Emdadi A, Soori B, Mostafavi E. Prevalence of Human Immunodeficiency Virus Infection among Injection Drug Users Released from Jail. Addiction & health. 2012; 4(3-4):151. PMID: 24494150
25. Farnia M, Shahbazi M, Moradi G, Alizadeh S, Ebrahi B, Kalle M. Evaluation of harm reduction programs in prisons from the attitude and viewpoint of Iranian prison staff. Journal of School of Public Health & Institute of Public Health Research. 2013;11(1). [in Persian]
26. Nunes EV, Sullivan MA, Levin FR. Treatment of depression in patients with opiate dependence. Biological Psychiatry. 2004; 56(10):793-802. 10.1016/j.biopsych.2004.06.037 [DOI:10.1016/j.biopsych.2004.06.037] [PMID]
27. Acosta MC, Marsch LA, Xie H, Guarino H, Aponte-Melendez Y. A web-based behavior therapy program influences the association between cognitive functioning and retention and abstinence in clients receiving methadone maintenance treatment. Journal of dual diagnosis. 2012; 8(4):283-93. 10.1080/15504263.2012.723317 [DOI:10.1080/15504263.2012.723317] [PMID] [PMCID]
28. Emdadi A. Prevalence of Human Immunodeficiency Virus Infection among Injection Drug Users Released from Jail. Addiction and Health. [in Persian].
29. Ross M. Health and health promotion in prisons: Routledge; 2012. [DOI:10.4324/9780203083239]
30. Hutton HE, Treisman GJ, Hunt WR, Fishman M, Kendig N, Swetz A, et al. HIV risk behaviors and their relationship to posttraumatic stress disorder among women prisoners. Psychiatric Services. 2001; 52(4):508-13. 10.1176/appi.ps.52.4.508 [DOI:10.1176/appi.ps.52.4.508] [PMID]
31. Grinstead OA, Zack B, Faigeles B, Grossman N, Blea L. Reducing postrelease HIV risk among male prison inmates: A peer-led intervention. Criminal Justice and Behavior. 1999;26(4):453-65. https://doi.org/10.1177/0093854899026004003 [DOI:10.1177%2F0093854899026004003]
32. Kamarulzam an A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. The Lancet. 2016;388(10049):1115-26. 10.1016/S0140-6736(16)30769-3 [DOI:10.1016/S0140-6736(16)30769-3]
33. Gough E, Kempf MC, Graham L, Manzanero M, Hook EW, Bartolucci A, et al. HIV and hepatitis B and C incidence rates in US correctional populations and high risk groups: a systematic review and meta-analysis. BMC Public Health. 2010;10(1):777. doi: 10.1186/1471-2458-10-777 [DOI:10.1186/1471-2458-10-777] [PMID] [PMCID]
34. Zafarghandi MB, Eshrati S, Vameghi M, Ranjbar H, Arezoomandan R, Clausen T, Waal H. Drug-related community issues and the required interventions in open drug scenes in Tehran, Iran: a qualitative study protocol. BMJ open. 2019 Oct 1;9(10):e030488. http://dx.doi.org/10.1136/bmjopen-2019-030488 [DOI:10.1136/bmjopen-2019-030488] [PMID] [PMCID]

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Journal of Psychiatry and Clinical Psychology

Designed & Developed by : Yektaweb